-
Health todayCancer confirms
Colorectal cancer screening in Lombardy over two decades, with performance and costs
Adjusted colorectal cancer incidence in Lombardy fell from 68.8 to 38.2 per 100,000 between 2007 and 2023.
Peer-reviewed -
Health todayCancer refines
GLP-1 receptor agonists and lung cancer in type 2 diabetes with pulmonary nodules
GLP-1 receptor agonists were linked to fewer lung cancers than metformin, but genetic and SGLT2 inhibitor comparisons gave no support.
Peer-reviewed -
Health todayCancer refines
Real-world immune checkpoint inhibitor survival is often poorer than in pivotal trials
Of 2,514 Belgian metastatic patients on immune checkpoint inhibitors, 568 stopped without further therapy and survived a median 21.4 months.
Preprint · not peer-reviewed -
Health todayCancer refines
First-line covalent BTK inhibitors for CLL are often stopped early in US community care
Among 584 US community oncology patients with CLL/SLL, half had stopped first-line ibrutinib, acalabrutinib or zanubrutinib by 24 months, most often because of adverse events.
Peer-reviewed -
Health todayCancer new
Early-onset colorectal tumours show more stromal cells and distinct gene expression
Colorectal tumours from younger adults held more stromal cells and expressed more long non-coding RNAs and epithelial-to-mesenchymal transition genes.
Peer-reviewed -
Health todayCancer refines
Cancer mortality gap across Japanese prefectures moved north between 1995 and 2023
As cancer mortality fell, Japan's prefectural excess moved from liver cancer in the west to several cancers in the north.
Peer-reviewed -
Health todayCancer refines
Surveillance mammography beyond 5 years and advanced second breast cancer in older women
In 9,888 older breast cancer survivors, continued mammography after 5 years was not linked to fewer advanced second primary cancers.
Peer-reviewed -
Health todayCancer refines
Cervical cancer cases and deaths worldwide in 2023, with forecasts to 2050
Worldwide, 887,000 new cervical cancer cases and 369,000 deaths were estimated for 2023, with rises forecast by 2050.
Peer-reviewed -
Health todayCancer refines
Oropharyngeal cancer incidence rising across Europe, with HPV behind 43% of cases
Registries reported 22,063 new oropharyngeal cancer cases in 29 European countries in 2024, 43.3% attributable to HPV.
Peer-reviewed -
Health todayCancer refines
Colorectal cancer PRS link wanes with onset age; additive gene-lifestyle interaction late
High versus low polygenic risk gave colorectal cancer hazard ratios of 3.72 before age 55 and 2.01 from 75.
Peer-reviewed -
Tomorrow's worldInnovation in treatment new
Individualised mRNA melanoma vaccine with pembrolizumab cuts recurrence or death by 42%
Adding intismeran autogene to pembrolizumab after melanoma was removed reduced recurrence or death risk by 42% in phase III INTerpath-0001.
Peer-reviewed -
Health todayCancer refines
Breast cancer survival by stage across Europe after harmonising registry TNM data
Ten-year relative survival of European women with breast cancer was 97% at stage I and 10% at stage IV.
Peer-reviewed